Advertisement Bio-Bridge wins approval for acquisition of Xinheng Baide - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Bio-Bridge wins approval for acquisition of Xinheng Baide

Bio-Bridge Science has received a certificate of approval from the Department of Commerce of Inner Mongolia Autonomous Region of the People's Republic of China for the acquisition of Xinheng Baide Biotechnology.

Bio-Bridge Science has one month to close the transaction, and obtain the new business license. The transaction is expected to close before the end of July 2008.

Liang Qiao, chairman and CEO of Bio-Bridge, said: “We are happy to see the Inner Mongolia government has approved our acquisition of Xinheng Baide. The completion of the acquisition of Xinheng Baide will be a significant first step of our acquisition strategy. We believe Xinheng Baide will provide revenues and complementary products to Bio-Bridge.”